Q-omics provides the consensus-scored UBA52P3 profile across patient tissues and cancer cell-line models. UBA52P3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, UBA52P3 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, UBA52P3 RNA expression shows 9,957 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, KIRC, and ACC as cancer lineages where UBA52P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBA52P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBA52P3 survival associations across molecular data types. UBA52P3 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBA52P3 RNA expression–survival associations across cancer types. High UBA52P3 expression shows unfavorable associations in KIRP, HNSC, ACC and PAAD, but favorable associations in CESC and SKCM. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for UBA52P3 RNA expression.
This table summarizes UBA52P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for UBA52P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBA52P3 shows lower tumor expression in LUAD, THCA and BLCA and higher tumor expression in KIRC, COAD and LIHC. The KIRC box plot shows higher UBA52P3 RNA expression in tumor versus normal tissue (log2 FC = +0.851, t-test p < 0.001).
This table shows molecular features associated with UBA52P3 in patient tissues and cancer cell lines. In patient samples, UBA52P3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
